Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | FAAH | O00519 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1097624 | 0.86 | KMT2A (0.48) | GAAFAAHALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6042948 | 0.83 | RAB9A (0.42) | GAARAB9ANPC1ALDH1A1MAPT | |
| SCHEMBL25268431 | 0.83 | RAB9A (0.42) | GAARAB9ANPC1ALDH1A1MAPT | |
| SCHEMBL6653645 | 0.82 | ALOX15 (0.50) | ALOX15GAAFAAHRAB9ANPC1 | |
| SCHEMBL7025914 | 0.82 | ALOX15 (0.50) | ALOX15GAAFAAHRAB9ANPC1 | |
| SCHEMBL6652430 | 0.82 | ALOX15 (0.50) | ALOX15GAAFAAHRAB9ANPC1 | |
| SCHEMBL3074809 | 0.81 | MEN1 (0.46) | PDE4B | |
| SCHEMBL3074806 | 0.81 | MEN1 (0.46) | PDE4B | |
| SCHEMBL6703817 | 0.79 | ALOX15 (0.45) | ALOX15GAAFAAHRAB9ANPC1 | |
| SCHEMBL6651925 | 0.79 | ALOX15 (0.43) | ALOX15GAAFAAHRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020010155-A1 | Novel process | SMITHKLINE BEECHAM P.L.C. | 2002-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010155-A1 | Novel process | ADH1C, CBR1, ADH1A | ALOX15 2020/4885GAA 4126/4885FAAH 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.